Valuation: Avenue Therapeutics, Inc.

Market Cap 923K 809K 746K 698K 1.31M 87.03M 1.34M 8.96M 3.47M 43.01M 3.46M 3.39M 149M P/E 2024
-0.22x
P/E 2025 -0.73x
Enterprise Value -1.93M -1.69M -1.56M -1.46M -2.74M -182M -2.8M -18.77M -7.26M -90.09M -7.26M -7.1M -312M EV / Sales 2024
-
EV / Sales 2025 -491,128x
Free-Float
86.49%
Yield 2024 *
-
Yield 2025 -
1 day-8.35%
1 week-14.00%
Current month-6.67%
1 month-26.32%
3 months-3.45%
6 months-56.37%
Current year-58.84%
1 week 0.26
Extreme 0.26
0.35
1 month 0.25
Extreme 0.25
0.44
Current year 0.15
Extreme 0.15
0.79
1 year 0.15
Extreme 0.15
0.97
3 years 0.15
Extreme 0.15
93.75
5 years 0.15
Extreme 0.15
3,161.26
10 years 0.15
Extreme 0.15
13,882.3
Manager TitleAgeSince
Chief Executive Officer 59 2022-07-31
Chief Executive Officer 36 2022-03-30
Investor Relations Contact - -
Director TitleAgeSince
Chairman 71 2015-02-08
Director/Board Member 69 2015-07-31
Chairman 68 2023-03-06
Date Insider Type Main position Quantity % Market Cap.
01-01FreeCompany 111,209 3.4934%
25-03-30FreeCompany 33,724 1.6419%
24-12-30OtherCompany 294,800 15.4214%
Change 5-day change 1-year change 3-year change Capi.($)
-8.35%-14.00%+16.47%-99.67% 923K
+0.33%+1.37%+63.66%+126.38% 55.63B
+0.82%+15.05%+79.52%+85.53% 52.25B
+1.36%+0.36%-14.52%-13.83% 23.07B
-1.04%+7.91%+3.91%+417.68% 22.41B
-0.18%+7.20%+31.37%-13.62% 17.32B
-1.10%+4.00%+29.97%-33.36% 15.94B
+2.89%+5.51%+25.42%+186.30% 13.77B
-3.35%+8.96%+134.32%+289.59% 13.47B
+1.31%+0.53%+27.83% - 12.43B
Average -0.73%+2.90%+39.80%+105.00% 22.63B
Weighted average by Cap. +0.26%+5.13%+48.50%+122.68%

Financials

2024 2025
Net sales - 1.4 1.23 1.13 1.06 1.99 132.44 2.03 13.64 5.28 65.46 5.27 5.16 226.97
Net income -11.65M -10.22M -9.42M -8.82M -16.53M -1.1B -16.88M -113M -43.8M -543M -43.75M -42.8M -1.88B -2.91M -2.55M -2.35M -2.2M -4.13M -274M -4.21M -28.26M -10.93M -136M -10.92M -10.68M -470M
Net Debt -2.59M -2.27M -2.1M -1.96M -3.68M -245M -3.76M -25.2M -9.75M -121M -9.74M -9.53M -419M -2.86M -2.5M -2.31M -2.16M -4.05M -269M -4.13M -27.73M -10.73M -133M -10.72M -10.49M -462M
Logo Avenue Therapeutics, Inc.
Avenue Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidate, intravenous tramadol (IV tramadol) is a novel therapy in development in the United States for managing post-operative pain as an alternative to conventional narcotics. The drug is designed to use a dual mechanism of action to block a patient’s pain signal with reduced abuse potential. This unique mechanism of action includes an opioid agonist and an inhibitor of norepinephrine and serotonin re-uptake.
Employees
1
Date Price Change Volume
26-06-26 US$0.2800 -8.35% 658
26-06-25 US$0.3055 -12.71% 3,117
26-06-24 US$0.3500 +9.37% 5,439
26-06-23 US$0.3200 +6.67% 2,997
26-06-22 US$0.3000 -7.85% 2,086

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ATXI Stock